CENA Research Institute: CENA Research Institute (CRI) bridging academia and industry. High-impact clinical research in pharmaceuticals, medical devices, and digital health. Rooted in inclusivity and real-world evidence.
Clinical research that includes everyone.
We help pharma recruit patients, support medical device and AI companies in validating products in the U.S., and conduct clinical trials—all with a patient-first, inclusive approach.
Who We Are
Cena Research Institute (CRI) is a multidisciplinary clinical research organization composed of physicians, scientists, and research staff conducting industry‑sponsored and investigator‑initiated studies across cardiovascular medicine, medical technology, and digital health.
CRI operates at the intersection of academic rigor and industry execution. Our research infrastructure is designed to support publication‑quality outcomes while remaining operationally aligned with sponsor timelines and regulatory expectations.
What We Do
We help pharmaceutical sponsors reach and enroll diverse patients for clinical studies.
We help medical device and AI companies validate their products for the U.S. market.
We conduct clinical trials with rigorous design and inclusive participation.
Local and Global Partners. Houston Advantage.
CRI supports both U.S. and international organizations in validating and scaling medical devices, digital health solutions, and therapeutic innovations.
From Houston, we connect innovators with diverse, multilingual patient populations to generate real-world, regulator-ready evidence.
Inclusivity strengthens results—and strengthens markets.
Why Clinical Research Inclusivity
Many clinical trials fail to reflect the populations ultimately served by healthcare innovations. CRI was established to address this gap by embedding inclusivity into study design, recruitment, and analysis.
Our research emphasizes participation from:
- Female patients
- Elderly populations
- Racial and ethnic minorities
- Underrepresented disease states
- Multilingual communities, including English, Spanish, Arabic, Vietnamese, and Hindi/Urdu
This approach produces data that is more generalizable, clinically relevant, and aligned with real‑world care delivery.
Selected Clinical Research Experience
International, randomized, sham‑controlled clinical trial evaluating alcohol‑mediated renal denervation. Results published in a peer‑reviewed cardiovascular journal.
Phase III outcomes trial evaluating abelacimab in patients with atrial fibrillation at high risk for stroke.
Large‑scale biometric validation studies across hypertensive and hypotensive populations.
Clinical investigations in heart failure, post‑transplant physiology, postural orthostatic tachycardia syndrome, and cognitive outcomes.
Peer‑Reviewed Research & Thought Leadership
CRI investigators contribute to peer‑reviewed literature and scientific discourse across cardiovascular medicine, artificial intelligence, and digital health.
Publications reflect independent scholarly work by CRI investigators. Journal appearance does not imply organizational endorsement.
Collaborate With CRI
CRI partners with pharmaceutical companies, medical device manufacturers, and digital health organizations to execute rigorous, inclusive clinical research—from early validation through publication‑ready outcomes.
Lone Star Summit
Lone Star Summit 2027
Houston HealthTech AI